Saturday 17 October 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
299.77
6.47
−2.11%
Follow CRL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (7.69%) | (6.01%) | (4.35%) | (2.48%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 5 | 4 | |
| (3.16%) | (2.41%) | (1.97%) | (1.15%) | ||
ROIC |
1.07% | 0.81% | 0.31% | 1.63% | |
Return on Tangible Assets |
(12.62%) | (9.69%) | (7.28%) | (4.45%) | |
Average Days of Receivables |
64.96 | 63.47 | 64.44 | 66.63 | |
Free Cash Flow per Share |
7.72 | 7.99 | 10.46 | 11.05 | |
Free Cash Flow |
370.61 | 391.29 | 518.49 | 543.67 | |
Capital Expenditures |
(211.54) | (215.74) | (219.15) | (205.82) | |
| Other line items | |||||
Cash ROIC |
6.55% | 6.74% | 9.39% | 9.37% | |
Accounts Receivable Turnover |
5.41 | 5.53 | 5.62 | 5.41 | |
Accounts Payable Turnover |
18.78 | 19.25 | 18.62 | 17.84 | |
Inventory Turnover |
8.60 | 8.39 | 9.32 | 8.54 | |
Average Days of Payables |
19.11 | 17.93 | 20.17 | 22.71 | |
Days of Inventory on Hand |
46.94 | 48.15 | 40.55 | 40.51 | |
Tax Rate |
0.29 | 0.11 | 0.43 | 2.59 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
19.06% | 18.00% | 18.51% | 18.46% | |
Share Based Compensation of Revenue |
2.08% | 1.99% | 1.77% | 1.76% | |
Interest Coverage |
0.85 | 0.66 | 0.24 | 1.26 | |
Operating CF/Net income |
(2.44) | (3.29) | (5.11) | (8.41) | |
Depreciation/Fixed assets |
0.31 | 0.34 | 0.34 | 0.40 | |
Capex/Depreciation |
(0.46) | (0.42) | (0.39) | (0.32) | |
Revenue per Share |
83.28 | 82.27 | 81.01 | 81.76 | |
Operating CF per Share |
12.12 | 12.40 | 14.88 | 15.23 | |
Capex per Share |
(4.41) | (4.41) | (4.42) | (4.18) | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.05 |
Columns are period end dates